Business Context and Reporting Period
This Form 8-K was filed by TRxADE HEALTH, INC. (noting a discrepancy with the request metadata which listed "Scienture Holdings, Inc.") on June 23, 2023. The report details the entry into a binding Letter of Intent (LOI) for a merger with Superlatus, Inc., a U.S.-based holding company focused on food products and distribution. The LOI was originally signed on June 22, 2023, and amended on June 23, 2023, to correct the share count for Superlatus shareholders.
Key Financial Metrics and Deal Terms
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or debt levels for the reporting period. Instead, it outlines the financial structure of the proposed merger:
- Consideration: Superlatus shareholders will receive 3,839,176 shares of TRxADE HEALTH, Inc.
- Valuation: Shares are valued at $58.61 per share.
- Ownership Structure: The consideration comprises common stock representing 19.99% of the post-merger total issued and outstanding common stock, with the remainder in a new class of non-voting preferred stock.
- Target Valuation Requirement: A condition for the definitive agreement is a third-party valuation report reflecting a value for the "Combined Targets" (Superlatus, Sapentia, Inc., and Prestige Farms) of at least $225 million.
Material Changes and Conditions
The primary material change is the initiation of merger discussions and the amendment of the LOI share count. The execution of a definitive merger agreement is subject to several material conditions:
- Completion of Superlatus's acquisition of Sapentia, Inc. and Prestige Farms within 45 days of the LOI date.
- Successful completion of due diligence (business, legal, tax, financial) including review of ongoing litigation.
- Delivery of audited financials for 2021 and 2022, and unaudited financials for the partial 2023 year.
- Confirmation that the Combined Targets are on pace to meet financial projections provided prior to the LOI.
- No occurrence of a material adverse effect on the Combined Targets.
Outlook, Risks, and Management Commentary
Management expects to announce additional details once a definitive merger agreement is executed. The LOI includes specific termination rights:
- Termination by mutual written agreement.
- Termination by TRxADE HEALTH, Inc. at any time at its sole discretion.
- Termination by Superlatus at the end of the 60-day due diligence period.
- Automatic termination upon execution of a definitive merger agreement.
Risks include the failure to meet the 45-day acquisition timeline for Sapentia and Prestige Farms, failure to achieve the $225 million valuation threshold, or the discovery of material adverse effects during due diligence.
Investor Verification Checklist
- Verify the correct registrant name (TRxADE HEALTH, Inc. vs. Scientificure Holdings, Inc.) and ticker symbol (MEDS).
- Confirm the status of Superlatus's pending acquisitions of Sapentia, Inc. and Prestige Farms.
- Monitor for the release of the independent third-party valuation report confirming the $225 million threshold.
- Review the upcoming definitive merger agreement for changes to the 19.99% common stock allocation and preferred stock terms.
- Check for any material adverse effect disclosures or litigation updates during the due diligence period.